CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS

Objective: To study clinical parameters of multiple myeloma progression in residents of the Gomel region of Belarus Methodology: The study included 159 MM patients who were examined at the State Institution “Republican Research Center for Radiation Medicine and Human Ecology”, Gomel from 2018 to 202...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhanna KOZICH, Victor MARTINKOV, Janna PUGACHEVA, Svetlana MIHNO, Anna DOMANTSEVICH, Ludmila SMIRNOVA
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/62203bd357ee4699bd6d8a5654f482ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:62203bd357ee4699bd6d8a5654f482ae
record_format	dspace
spelling	oai:doaj.org-article:62203bd357ee4699bd6d8a5654f482ae2021-11-10T04:36:15ZCLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS2531-137910.1016/j.htct.2021.10.1041https://doaj.org/article/62203bd357ee4699bd6d8a5654f482ae2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011883https://doaj.org/toc/2531-1379Objective: To study clinical parameters of multiple myeloma progression in residents of the Gomel region of Belarus Methodology: The study included 159 MM patients who were examined at the State Institution “Republican Research Center for Radiation Medicine and Human Ecology”, Gomel from 2018 to 2021. The average age was 62. Female patients prevailed and amounted 57.1%. MM was diagnosed according to international criteria. The criteria for progression were determined when new foci of destruction or extramedullary lesions appeared, and at an increase in the number of plasma cells in the bone marrow> 10%. Results: Progression was in 10.7%(17). No differences in the immunological variant of MM. CD20 expression>20% was found 6.18 more often in progressed patients (p=0.0001). CD56>20% was 2.37 more common at progression (p=0.006). CD117>20% was 2.34 more often at progression, (p=0.116). M-protein>15 g/l was 6.22 more often at progression (p = 0.0001). Abnormal κ/λ was in 81.3% at progression (p=0.027). LDH was different (p=0.023). Kidney damage and destructive syndrome did not affect progression (p=0.797). Conclusion: Identification of markers of progression at the initial examination, such as excess expression of CD20> 20%, CD56> 20%, excess of M-protein> 15 g/l, abnormal κ/λ ratio can predetermine the outcome of the disease. Our findings are consistent with the literature data, but much remains unclear, for instance, cases with normal LDH values in patients with progression. This gives rise to future research.Zhanna KOZICHVictor MARTINKOVJanna PUGACHEVASvetlana MIHNOAnna DOMANTSEVICHLudmila SMIRNOVAElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S44- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Zhanna KOZICH Victor MARTINKOV Janna PUGACHEVA Svetlana MIHNO Anna DOMANTSEVICH Ludmila SMIRNOVA CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS
description	Objective: To study clinical parameters of multiple myeloma progression in residents of the Gomel region of Belarus Methodology: The study included 159 MM patients who were examined at the State Institution “Republican Research Center for Radiation Medicine and Human Ecology”, Gomel from 2018 to 2021. The average age was 62. Female patients prevailed and amounted 57.1%. MM was diagnosed according to international criteria. The criteria for progression were determined when new foci of destruction or extramedullary lesions appeared, and at an increase in the number of plasma cells in the bone marrow> 10%. Results: Progression was in 10.7%(17). No differences in the immunological variant of MM. CD20 expression>20% was found 6.18 more often in progressed patients (p=0.0001). CD56>20% was 2.37 more common at progression (p=0.006). CD117>20% was 2.34 more often at progression, (p=0.116). M-protein>15 g/l was 6.22 more often at progression (p = 0.0001). Abnormal κ/λ was in 81.3% at progression (p=0.027). LDH was different (p=0.023). Kidney damage and destructive syndrome did not affect progression (p=0.797). Conclusion: Identification of markers of progression at the initial examination, such as excess expression of CD20> 20%, CD56> 20%, excess of M-protein> 15 g/l, abnormal κ/λ ratio can predetermine the outcome of the disease. Our findings are consistent with the literature data, but much remains unclear, for instance, cases with normal LDH values in patients with progression. This gives rise to future research.
format	article
author	Zhanna KOZICH Victor MARTINKOV Janna PUGACHEVA Svetlana MIHNO Anna DOMANTSEVICH Ludmila SMIRNOVA
author_facet	Zhanna KOZICH Victor MARTINKOV Janna PUGACHEVA Svetlana MIHNO Anna DOMANTSEVICH Ludmila SMIRNOVA
author_sort	Zhanna KOZICH
title	CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS
title_short	CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS
title_full	CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS
title_fullStr	CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS
title_full_unstemmed	CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS
title_sort	clinical parameters of multiple myeloma progression in residents of the gomel region of belarus
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/62203bd357ee4699bd6d8a5654f482ae
work_keys_str_mv	AT zhannakozich clinicalparametersofmultiplemyelomaprogressioninresidentsofthegomelregionofbelarus AT victormartinkov clinicalparametersofmultiplemyelomaprogressioninresidentsofthegomelregionofbelarus AT jannapugacheva clinicalparametersofmultiplemyelomaprogressioninresidentsofthegomelregionofbelarus AT svetlanamihno clinicalparametersofmultiplemyelomaprogressioninresidentsofthegomelregionofbelarus AT annadomantsevich clinicalparametersofmultiplemyelomaprogressioninresidentsofthegomelregionofbelarus AT ludmilasmirnova clinicalparametersofmultiplemyelomaprogressioninresidentsofthegomelregionofbelarus
_version_	1718440561612947456

CLINICAL PARAMETERS OF MULTIPLE MYELOMA PROGRESSION IN RESIDENTS OF THE GOMEL REGION OF BELARUS

Ejemplares similares